Cargando…

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

BACKGROUND: When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and predictive of response to treatment, our aim was to develop an immunologic tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaye, C., Darbo, É., Debled, M., Brouste, V., Vélasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., Commeny, J., Bonnefoi, H., Larmonier, C., MacGrogan, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434232/ https://www.ncbi.nlm.nih.gov/pubmed/35759853 http://dx.doi.org/10.1016/j.esmoop.2022.100502

Ejemplares similares

Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives
por: Boyer, Thomas, et al.
Publicado: (2022)

Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers
por: Blaye, Céline, et al.
Publicado: (2022)

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
por: Bellera, Carine A, et al.
Publicado: (2010)

Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity
por: Moisand, Alexandra, et al.
Publicado: (2023)

Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria
por: de Mascarel, Isabelle, et al.
Publicado: (2015)

Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells
por: Larmonier, Nicolas, et al.
Publicado: (2012)

The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer
por: Alizadeh, Darya, et al.
Publicado: (2013)

Chemotherapeutic targeting of myeloid-derived suppressor cells
por: Alizadeh, Darya, et al.
Publicado: (2014)

Editorial: Tumor-promoting immune cells: Cancer immune escape and beyond
por: Domblides, Charlotte, et al.
Publicado: (2023)

Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death
por: Rondeau, Virginie, et al.
Publicado: (2010)

The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
por: Janikashvili, Nona, et al.
Publicado: (2011)

Characterizing causality in cancer
por: Rondeau, Elena, et al.
Publicado: (2019)

Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells
por: Verbeke, Stephanie, et al.
Publicado: (2014)

Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells
por: Verbeke, Stephanie, et al.
Publicado: (2015)

T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome
por: Larmonier, C. B., et al.
Publicado: (2015)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

T Lymphocyte Plasticity in Autoimmunity and Cancer
por: Janikashvili, Nona, et al.
Publicado: (2015)

Beyond the tumour microenvironment
por: Laplane, Lucie, et al.
Publicado: (2019)

An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis
por: Bonnet, Françoise, et al.
Publicado: (2012)

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers
por: Puccetti, Paolo, et al.
Publicado: (2015)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

The CERN/ISOLDE Laser Ion Source
por: Marsh, B A, et al.
Publicado: (2017)

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
por: Bonnefoi, Hervé, et al.
Publicado: (2019)

Interleukin-2/Anti-Interleukin-2 Immune Complex Expands Regulatory T Cells and Reduces Angiotensin II-Induced Aortic Stiffening
por: Majeed, Beenish, et al.
Publicado: (2014)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Functional aortic stiffness: role of CD4(+) T lymphocytes
por: Majeed, Beenish A., et al.
Publicado: (2015)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients
por: de Mascarel, I, et al.
Publicado: (2002)

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
por: Quenel-Tueux, Nathalie, et al.
Publicado: (2015)

Identification of molecular apocrine breast tumours by microarray analysis
por: Farmer, P, et al.
Publicado: (2005)

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
por: Anand, Kartik, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis
por: Debled, M, et al.
Publicado: (2007)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
por: Park, Seho, et al.
Publicado: (2016)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2021)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False
por: Desjardin, Marie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_igjqum1b5u80n8jgk3l05uhdes